Review ArticleClinical Review
Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician
Martina Mookadam, Fadi E. Shamoun and Farouk Mookadam
The Journal of the American Board of Family
Medicine July 2015, 28 (4) 510-522; DOI: https://doi.org/10.3122/jabfm.2015.04.140297
Martina Mookadam
From the Department of Family Medicine (MM) and the Division of Cardiovascular Diseases (FES, FM), Mayo Clinic, Scottsdale, AZ.
MDFadi E. Shamoun
From the Department of Family Medicine (MM) and the Division of Cardiovascular Diseases (FES, FM), Mayo Clinic, Scottsdale, AZ.
MDFarouk Mookadam
From the Department of Family Medicine (MM) and the Division of Cardiovascular Diseases (FES, FM), Mayo Clinic, Scottsdale, AZ.
MD, MSc (HRM), FRCPCReferences
- 1.↵
- Fuster V,
- Rydén LE,
- Cannom DS,
- et al
- 2.↵
- Camm AJ,
- Kirchhof P,
- Lip GY,
- et al
- 3.↵
- Lip GY,
- Tse HF,
- Lane DA
- 4.↵
- Gladstone DJ,
- Bui E,
- Fang J,
- et al
- 5.↵
- Miyasaka Y,
- Barnes ME,
- Gersh BJ,
- et al
- 6.↵
- Aberg H
- 7.↵
- Stoddard MF,
- Dawkins PR,
- Prince CR,
- Ammash NM
- 8.↵2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Washington, DC: Heart Rhythm Society. Available from: http://www.hrsonline.org/Practice-Guidance/Clinical-Guidelines-Documents/Focused-Update-on-the-Management-of-Patients-With-Atrial-Fibrillation/2014-Guideline-for-the-Management-of-Patients-With-AFib#axzz3cCj7Luwn. Accessed May 15, 2015.
- 9.↵
- Lane DA,
- Lip GY
- 10.↵
- Hart RG,
- Pearce LA,
- Asinger RW,
- Herzog CA
- 11.
- Lip GY
- 12.↵
- Pisters R,
- Lane DA,
- Nieuwlaat R,
- de Vos CB,
- Crijns HJ,
- Lip GY
- 13.↵
- Banerjee A,
- Lane DA,
- Torp-Pedersen C,
- Lip GY
- 14.↵
- Hirsh J,
- Dalen J,
- Anderson DR,
- et al
- 15.↵
- Heneghan C,
- Alonso-Coello P,
- Garcia-Alamino JM,
- Perera R,
- Meats E,
- Glasziou P
- 16.↵
- 17.↵
- Hohnloser SH
- 18.↵
- Waldo AL,
- Becker RC,
- Tapson VF,
- Colgan KJ
- 19.↵
- Glader EL,
- Sjolander M,
- Eriksson M,
- Lundberg M
- 20.↵
- Ogilvie IM,
- Newton N,
- Welner SA,
- Cowell W,
- Lip GY
- 21.↵
- Connolly SJ,
- Pogue J,
- Hart RG,
- et al
- 22.↵
- Connolly S,
- Pogue J,
- Hart R,
- et al
- 23.↵
- 24.↵
- Albers GW,
- Diener HC,
- Frison L,
- et al
- 25.↵
- Olsson SB
- 26.↵
- Gorelick PB
- 27.↵
- Munar MY,
- Singh H
- 28.↵
- Connolly SJ,
- Ezekowitz MD,
- Yusuf S,
- et al
- 29.↵
- Eikelboom JW,
- Weitz JI
- 30.↵
- Granger CB,
- Alexander JH,
- McMurray JJ,
- et al
- 31.↵
- Patel MR,
- Mahaffey KW,
- Garg J,
- et al
- 32.↵
- Schirmer SH,
- Baumhakel M,
- Neuberger HR,
- et al
- 33.↵
- Southworth MR,
- Reichman ME,
- Unger EF
- 34.↵
- Weitz JI,
- Connolly SJ,
- Patel I,
- et al
- 35.↵
- Eikelboom JW,
- Wallentin L,
- Connolly SJ,
- et al
- 36.↵
- Hijazi Z,
- Hohnloser SH,
- Oldgren J,
- et al
- 37.↵
- Gage BF,
- Waterman AD,
- Shannon W,
- Boechler M,
- Rich MW,
- Radford MJ
- 38.↵Product monograph. Pradaxa (dabigatran etexilate capsules). Burlington, ON: Boehringer Ingelheim Canada Ltd. Revised January 7, 2015. Available from: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdf. Accessed March 15, 2015.
- 39.↵Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban). Revised January 2015. Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed March 15, 2015.
- 40.↵Product monograph. Eliquis (apixaban tablets). Montreal: Bristol-Myers Squibb Canada. February 20, 2015. Available from: http://www.pfizer.ca/en/our_products/products/monograph/313. Accessed May 15, 2015.
- 41.↵Daiichi Sankyo Inc. SAVAYSA (edoxaban). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed May 15, 2015.
- 42.↵
- Heidbuchel H,
- Verhamme P,
- Alings M,
- et al
- 43.↵
- Ansell J
- 44.↵
- Go AS,
- Singer D,
- Cheetham C,
- et al
- 45.↵
- Hernandez I,
- Baik SH,
- Pinera A,
- Zhang Y
- 46.↵
- Baron TH,
- Kamath PS,
- McBane RD
- 47.↵
- Spyropoulos AC,
- Douketis JD
- 48.↵
- Crowther M,
- Mathur V,
- Kitt MM,
- et al
- 49.↵
- 50.↵
- Lip GY,
- Agnelli G
- 51.↵
- Knepper J,
- Horne D,
- Obi A,
- Wakefield TW
- 52.↵Boehringer Ingelheim. Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation. June 26, 2014. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/06-26-14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fda-breakthrough-therapy-designation.html. Accessed May 15, 2015.
- 53.↵
In this issue
Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician
Martina Mookadam, Fadi E. Shamoun, Farouk Mookadam
The Journal of the American Board of Family
Medicine Jul 2015, 28 (4) 510-522; DOI: 10.3122/jabfm.2015.04.140297
Jump to section
Related Articles
- No related articles found.